J. Garnsey

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Amanda Doucette, Mansoureh Rezaei, Alice McDonald, 2009, Nature.

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.

Mark Manfredi, Lenny Dang, Usha Narayanan, 2010, Blood.

4924 , a NEDD 8-activating enzyme inhibitor , is active in diffuse large B-cell lymphoma models : rationale for treatment of NF-B – dependent lymphoma *

L. Staudt, U. Narayanan, L. Dang, 2010 .

Pre-Clinical Antitumor activity of MLN4924, An Inhibitor of NEDD8-Activating Enzyme (NAE), in a Novel Primary Human DLBCL Xenograft Model.

Peter G. Smith, A. Berger, J. Garnsey, 2009 .

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.

Francis J Giles, Peter G. Smith, J. Garnsey, 2010, Blood.

4924 , a NEDD 8-activating enzyme inhibitor , is active in diffuse large B-cell lymphoma models : rationale for treatment of NF-B – dependent lymphoma *

L. Staudt, U. Narayanan, L. Dang, 2010 .

A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models

Steven S. Langston, Xingyue He, E. Lightcap, 2021, Science Translational Medicine.

KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism

S. Tirrell, A. Berger, J. Garnsey, 2015, PloS one.